nucleoside reverse transcriptase inhibitors such as stavudine or zidovudine, together with 54 lamivudine was the preferred regimen for treatment-naïve patients, in part because of the 55 availability of WHO prequalified low-cost generic fixed-dose combination (1, 2). In 56 addition, single dose nevirapine administered to pregnant, HIV-infected women at delivery 57 has been widely prescribed to prevent mother-to-child transmission (3-6). Despite its major 58 therapeutic benefits, treatment with nevirapine may cause severe hepatotoxicity and/or skin 59 rash in some patients. Molecular mechanisms of nevirapine toxicity is incompletely 60 understood, but causal role of metabolites has been suggested (7, 8) . 61
Despite its widespread use, there remain gaps in understanding of nevirapine 62 metabolism and disposition. Its pharmacokinetic characteristics include a long plasma half-63 life after single dose administration, which decreases with repeated doses due to 64 autoinduction of its biotransformation (6, 9-11). Nevirapine is 60% bound to plasma 65 proteins, and elimination occurs mainly through oxidative metabolism. Group B patients were on chronic, steady-state antiretroviral therapy with 94 nevirapine 200 mg twice-daily plus two nucleoside analogs (lamivudine with either 95 stavudine or zidovudine) for about 3 years, and agreed to participate to this extensive 96 pharmacokinetic study as part of the ANRS12154 study. In that study, plasma HIV-1 RNA 97
was measured in addition to standard laboratory tests. 98
Plasma samples from group A subjects were obtained at 0.5, 1, 2, 4, 6, 8, 12 and 24 99 hours and on days 2, 3, 5, 7, 9 and 13 after a single dose of nevirapine. Plasma samples 100 from group B subjects were collected at pre-dose and at 1, 2, 4 and 8 hours after the 101 morning nevirapine dose. 102
103

Assay of nevirapine and metabolites in plasma
104
Plasma nevirapine assays for group A were performed in the United States (17), and 105 for group B were performed in Cambodia (18), both by liquid chromatography according to 106 previously validated assays. The lower limit of quantification was 50 ng/mL. Standard 107 curves were linear up to 5,000 ng/mL (17) or 10,000 ng/mL (18 Metabolic index was defined as the ratio of metabolite AUC to nevirapine AUC. For 126 consistency in group A, AUC 0-t to the same last time "t" of concentration detection was 127 used for metabolites and nevirapine to calculate metabolic indices, due to inability to 128 accurately determine the terminal rate constants ( z ) for metabolites that were detected at 129 very low concentrations. The maximum plasma concentration (C max ), the observed pre-dose 130 concentration (C 0 ), and time to C max (T max ) were obtained from visual inspection of 131 10 individuals in each group to detect major differences in nevirapine metabolite 138 disposition. 139
Pharmacokinetic parameters for nevirapine and its metabolites were described by 140 medians and ranges. Parameters were compared between group A and group B using the 141 non-parametric Wilcoxon rank-sum test. When appropriate, associations between 142 pharmacokinetic parameters were examined using a Spearman correlation test. All analyses 143 were performed using Statgraphics 5 plus (Manugistics, Inc., Maryland, USA). 144
145
Results
146
Study subject characteristics median half-lives of some metabolites tended to be shorter than that of nevirapine, these 183 differences were not statistically significant. In group B we could not calculate half-lives 184 for nevirapine or its metabolites, as the dosing interval was too short. 185
The nevirapine AUC 12 in group B was significantly less than the AUC inf in group 186 A, and Cl/F was significantly greater in group B than in group A (0.83 mL/min/kg and 0.29 187 mL/min/kg, respectively, p<0.001), indicating non-linear pharmacokinetics and 188 autoinduction. The 3-hydroxynevirapine AUC 12 in group B was greater than the 3-189 hydroxynevirapine AUC inf in group A, although this difference was not significant. In 190 contrast, the 2-hydroxynevirapine AUC 12 was 95% lower in group B than the 2- 557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583 
